Selection of men for investigation of possible testicular cancer in primary care: a large case-control study using electronic patient records by Shephard, EA & Hamilton, WT
Selection of men for investigation of possible testicular cancer in primary care:  a large case-
control study using electronic patient records.  
 
 
Elizabeth A Shephard, PhD, CPsychol, Research Fellow 
William T Hamilton, MD, FRCP, FRCGP, Professor of Primary Care Diagnostics 
 
University of Exeter Medical School 
College House 





Correspondence to Dr Shephard 
Email: E.A.Shephard@exeter.ac.uk  












Testicular cancer incidence has risen over the last two decades and is expected to continue to rise. 
There are no primary care studies on the clinical features of testicular cancer, with recent NICE 
guidance based solely upon clinical consensus. 
 
Aim 
To identify clinical features of testicular cancer and to quantify their risk in primary care patients, 
with the aim of improving the selection of patients for investigation.  
 
Design and setting 




Putative clinical features of testicular cancer were identified and analysed using conditional logistic 
regression. Positive predictive values (PPVs) were calculated for those aged under 50.  
 
Results 
1,398 cases were available, diagnosed between 2000 and 2012, with 4,956 age, sex and practice-
matched controls. Nine features were independently associated with testicular cancer, the top three 
being: testicular swelling, odds ratio 280 (95% confidence interval 110,690), testicular lump 270 
(100,740) and scrotal swelling 170 (35,800).  The highest PPV for 17-49 year olds was testicular lump 
2.5% (1.1-5.6). Combining testicular lump with testicular swelling or testicular pain produced PPVs of 
17% and 10% respectively. 
 
Conclusion 
Testicular enlargement carries a risk of cancer of 2.5% - near the current 3% threshold in UK referral 
guidance. Contrary to traditional teaching, painful testicular enlargement may signify cancer. Some 
initial hydrocele diagnoses appear to be wrong, with missed cancers, suggesting an ultrasound may 
be useful where a hydrocele diagnosis is uncertain. These results support the existing NICE 
guidelines, and help to characterise when an ultrasound should be considered in symptomatic men.  
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How this fits in 
There are no primary care studies on the testicular cancer prodrome, so NICE had difficulty in giving 
recommendations for investigation of testicular symptoms, in NG12, the recent guidance. This 
suggested referral for enlargement, and a primary care ultrasound for persistent or unexplained 
other testicular symptoms, though these symptoms were not further defined.  
Most of the symptoms of testicular enlargement or swelling have risks of cancer around 3%, 
supporting NICE’s recommendation for urgent referral.  Our Risk Assessment Tool shows some 
combinations of symptoms (some of which NICE has not considered) have risks above 3%, also 
warranting urgent referral. It also shows several symptom combinations with risks of testicular 








Testicular cancer is the 16th most common cancer in UK males. Over 2,400 new cases are diagnosed 
annually, nearly half in those under 35.(1)  Incidence rates in Great Britain have risen by 28% since 
the late 1990s and are expected to rise by 12% over the next two decades.(2)  Survival is highest in 
younger men: 98% of under 50 year olds survive for five years or more.(3) This high survival does not 
eliminate the benefit to be had from timely diagnosis: complications, such as thromboses, may 
arise.(4) 
For testicular cancer, diagnosis requires symptomatic presentation, usually to primary care. The 
National Institute for Health and Care Excellence (NICE) provide evidence-based guidelines to aid GP 
decision making – with the aim of improving patient outcomes. The current NICE guidance for 
testicular cancer recommends urgent specialist referral for men with non-painful enlargement or a 
change in shape or texture of the testis. A direct access ultrasound should be considered for men 
with persistent or unexplained other testicular symptoms.(5) These recommendations were made by 
consensus, as the guideline development group could find no primary care evidence on the features 
of testicular cancer. 
GPs typically investigate testicular symptoms promptly – during 2010 only 16% of testicular cancer  
patients visited their GP three or more times before referral.(6) The median time to diagnosis for 
testicular cancer (44 days) is one of the shortest for all cancers.(7) For one study, however, the time 
to diagnosis increased by over 36 days when non-NICE recommended symptoms were present.(8)  
The sole primary care study of cancer symptoms merged all types of cancer together, reporting an 
increased risk of testicular cancer in patients with testicular lump (185-fold), testicular pain (16-fold) 
and venous thrombo-embolism (9-fold).(9) Symptoms of testicular cancer reported from secondary 
care studies include back pain, leg pain, lethargy, fatigue, weight loss, testicular swelling, testicular 
pain, gynaecomastia, abdominal pain, painless nodule, testicular lump, painless scrotal mass and 
scrotal pain.(10-13) However, these studies were small, ranging between 6 and 140 patients. Serum 
tumour biomarkers such as alpha-fetoprotein (AFP), human chorionic gonadotrophin (hCG) and 
lactate dehydrogenase (LDH) have been found to be elevated in patients with testicular cancer.(14, 
15).  
This study aimed to identify clinical features of testicular cancer in primary care and to quantify their 












This was a matched case-control study using primary care electronic patient records from the UK’s 
Clinical Practice Research Datalink (CPRD), mirroring our previous cancer studies.(16-23) The CPRD 
contains anonymised medical records of patients from participating practices across the UK, 
representing roughly 8.8% of the population. Information is stored for clinical events such as 
symptoms, investigations, prescriptions and diagnoses, together with patient demographics.  
 
Cases and controls 
A list of 22 testicular cancer diagnostic codes (available from the authors) was collated from the 
CPRD master code library and used to identify patients. Cases were selected if aged ≥16 years 
(though the youngest transpired to be 17), diagnosed with testicular cancer between 2000 and 2012, 
and having consulted their GP in the year before the diagnosis date. Up to five, age, sex and general 
practice match controls were assigned to each case. The first testicular cancer code was taken as the 
date of diagnosis, or the ‘index date’. Controls were matched to their case’s index date. Exclusion 
criteria were: controls with a previous testicular cancer diagnosis, controls not consulting their GP in 
the year before the case index date, cases with no controls and cases or controls with missing 
relevant data. Three female cases, two with tunica vaginalis cancers, which can occur in either sex, 
and one with a tumour in an undescended testis were excluded.  
 
Selection of possible features of testicular cancer 
All previously reported diagnostic features of testicular cancer identified through literature searches 
were studied following PubMed, EBSCO and Google Scholar searches using the terms; ‘testicular 
cancer primary care’, ‘testicular cancer symptoms’, and, ‘early signs/symptoms/features of testicular 
cancer’. Self-reported symptoms described on online cancer support group forums were also 
included, allowing for new features to be included. Libraries of codes representing each candidate 
feature were assembled from the CPRD master list of over 100,000 medical codes. Occurrences of 
these codes were identified in the year before the index date. Features in fewer than 2% of cases 
were deemed too rare to draw useful conclusions from and were excluded.  
Records of fractures were compiled to test for any recording bias between cases and controls, with 
the assumption that fractures would be approximately equal in cases and controls. For laboratory 
tests, results outside each laboratory’s normal range were considered abnormal. Patients without a 
test result were grouped with those having a normal result. Some tests were grouped together: 
inflammatory markers comprised of any of erythrocyte sedimentation rate, C-reactive protein or 
plasma viscosity; liver function tests (LFT) comprised of any of the hepatic enzymes. LDH was 
examined separately as it is the only one of the three biomarkers routinely available in the full blood 
count test.  
 
Analysis 
The main analysis used conditional logistic regression. Features independently associated with 
testicular cancer in univariable analyses with a P-value of ≤0.1 were entered into multivariable 
analysis. Features were assembled into broad clinical groups (e.g., ‘Pain’: abdominal pain, groin pain, 
testicular pain), for the first stage of multivariable analysis, with a P-value threshold of ≤0.05 
required for entry into to the final stage of modelling. The final multivariable model contained all 
features surviving the earlier analyses, and used a P-value of ≤0.01 for final retention. Excluded 
variables were checked against the final model. Clinically plausible interactions were tested against 
the final model, also using a P-value threshold of ≤0.01. 
 
Calculation of positive predictive values (PPVs) 
Risk estimates for features associated with testicular cancer in patients consulting in primary care 
can be calculated using Bayes’ theorem (prior odds for a given feature x likelihood ratio = posterior 
odds of having the disease). The prior odds were calculated using the age-specific national incidence 
rate for testicular cancer in 2008. (CRUK, 2008). PPVs within the Risk Assessment Tool (RAT) were 
calculated for men aged 17-49. This age range allowed for over 81% of the testicular cancer patients 
to be represented in a single figure, maximising clinical utility. The PPVs were calculated for 
consulting patients aged 17-49 only. Thus the posterior odds were divided by 0.70, based on only 
3,915 out of 5,601 (70%) controls in that age group having seen their GP in the previous year, while 
all cases had done so. PPVs for selected single and combined features in the 50+age group were also 
estimated, though with wider confidence intervals. Analyses were performed using Stata (version 
14).  
Power calculations were used rather than sample size calculations. The CPRD provided estimates of 
1500 cases. Using a case-control ratio of 1:4, and 5% two sided alpha, these numbers provided >99% 
power to detect a change in prevalence of a rare variable of 3% in cases and 1% of controls. For 
commoner variables, this size has 95% power to detect a change from 20% prevalence in cases to 







The CPRD provided 8,300 patients: 1,428 cases and 6,872 controls. The application of exclusions is 
shown in Figure 1. A final number of 1,398 cases and 4,956 controls were studied. 
     Figure 1 here 
The median ages of cases and controls was 39 and 40, respectively. Cases consulted twice as often as 
controls in the year before diagnosis (8 to 4, respectively; P<0.001; rank-sum test). 
 
Clinical features 
Thirty-one symptoms and twenty-two investigations were studied. Nine remained significant in the 
multivariable final model. Of the 1,398 cases, 938 (67%) consulted their GP with at least one of these 
final model features in the year before their diagnosis. Table 1 shows the frequencies, univariable 
likelihood ratios and multivariable odds ratios of the nine final model features. There was a strong 
antagonistic interaction between testicular pain and testicular swelling, (interaction OR 0.008, 
P<0.001), meaning the predictive power when both features are present is less that would be 
expected from simply multiplying the two odds ratios.  Seventy-one cases (5%) and seven controls 
(0.1%) had a recorded LDH code. Of those, twenty-seven were abnormally raised, all belonging to 
cases (2%). LDH was dropped from further analyses. One hundred and seventy eight (13%) cases had 
a diagnosis of either hydrocele (25), epididymis or epididymis-orchitis (150) or both (3; added to the 
hydrocele group for analysis). For epididymis/epididymis-orchitis, 106 (71%) were recorded within 
three months preceding the cancer diagnosis. For the hydrocele group (n=28), 17 (61%) of these 
codes were recorded in the three months before diagnosis. 
Cases were grouped according to tumour type. Of the 1,398 cases, 684 (49%) had a generic code for 
testicular cancer, not specifying the histological subtype; 568 (41%) were seminomas; 122 (8%) were 
teratomas, 22 (2%) were in-situ, and 2 (0.1%) were classed as secondary malignant neoplasms. A 
sensitivity analysis excluded in-situ cases; the model did not significantly differ with the exclusion of 
these cases. Twenty-one cases (1.5%) and seventy-six controls (1.53%) had a record of a fracture 
(P<0.94).  
     Table 1 here 
Positive predictive values 
PPVs for individual and combined features of testicular cancer in men aged 17-49 are shown in 
Figure 2. The risk for a single symptom is shown in the top line, with paired features shown below. 
Testicular lump, testicular swelling and hydrocele each produced risk estimates above 1% (2.5%, 
2.3% and 1.1%, respectively). For the combined features, the highest PPVs were produced when 
testicular lump was recorded with other symptoms: testicular swelling (17%); testicular pain (10%); 
abdominal pain (6.1%). Testicular pain plus abdominal pain together also produced a PPV of 6.1%. 
PPVs for repeat consultations of testicular pain (1.1%) and the epididymis group (1%) are also 
shown. PPVs for single features in the 50+ age group were mostly under 1%, except for scrotal 
swelling, at 2.1%. In contrast to the younger group, combining testicular lump with testicular pain or 
testicular swelling reduced the PPV to 0.7% and 0.3%, respectively. Testicular swelling with 
orchidis/epididymitis produced the highest combined PPV, of 1.3% in this 50+ group. 








This is the first study to report the clinical features of testicular cancer in primary care. Certain 
secondary care reported symptoms were also associated with testicular cancer in primary care: PPVs 
for testicular lump and testicular swelling were both over 2%. This risk increased greatly when 
testicular lump was combined with other symptoms, such as testicular pain (10%). Other non-lump 
combinations also had risk estimates above the NICE 3% threshold for urgent referral, including 
testicular pain with raised inflammatory markers or groin pain (both 3.7%). New significant findings 
of hydrocele and epididymis-orchitis, especially prevalent in the three months before testicular 
cancer diagnosis, suggest a possible misdiagnosis (former) or a possible complication of the cancer 
(latter). 
 
Strengths and limitations 
This was a very large study with nearly 1,400 patients, with ample power. The quality and validity of 
CPRD data has been well reported.(24-26) The CPRD contains patients from across the UK, increasing 
the generalisability of the results. Staging information was unavailable, though arguably this is less 
important than for other cancers, as advanced stage testicular cancer is often curable. Furthermore 
we had no ethnicity data. 
The study is dependent upon the quality of primary care recording of symptoms with the possibility 
that there is missing data (27, 28). It is possible to record clinical details in a field that is irretrievable 
to researchers (the ‘free-text’). This loss of data matters if recording styles are unequal between 
cases and controls. One study in the CPRD itself has shown relative minor differential recording, with 
recognised high risk features of cancer being disproportionately recorded in cases.(29) This 
disproportion tends to inflate PPVs of high-risk features and (to a lesser extent) depress PPVs of low 
risk symptoms. The methods used here for estimating PPVs are well-established; however, despite 
the large population, several symptom combinations were too rare for reliable PPV estimates, 
particularly in the 50+ age group. 
Similarly, studying existing records meant accepting the records verbatim. This was most relevant in 
the three variables relating to swellings: testicular lump, testicular swelling and scrotal swelling. On 
paper, these mean different things, but it is possible general practitioners use them interchangeably, 
especially the first two. The strengths of the associations with cancer for ‘swelling’ and ‘lump’ were 
very similar, so the distinction between the two may be relatively unimportant.  That said, when the 
enlargement was accompanied by pain, GPs seemed to use the term swelling differently from the 
word lump, with the former combination being much lower risk. The timings of the reported 
combined symptoms for each individual were not investigated as previous analyses have shown it 
adds relatively little.  
By identifying patient reported symptoms using online forums, in addition to literature reviews, 
pertinent features were unlikely to have been omitted. Finally, cases consulted more often: thus 
their doctors had more opportunity to record symptoms than for controls, potentially introducing 
recording bias, though the proxy for this – fractures – was reassuring.  
 
Comparison with existing literature 
Cases had approximately twice as many primary care consultations in the year before diagnosis than 
controls. This is somewhat at odds with a previous report that patients with testicular cancer have 
one of the lowest percentage of cases (16%) requiring three or more GPs visits before diagnosis.(6) 
The findings from this paper suggest there remain opportunities for earlier diagnosis.  
Testicular pain has previously been reported in primary care as having a 16-fold increased risk of 
testicular cancer.(9) In this study, it had a multivariable odds-ratio of 38 (22-68), and a PPV of 0.4%. 
The relatively low PPV, despite a high odds ratio, reflects the rarity of testicular cancer. An 
association with testicular cancer has not previously been reported for hydrocele or epididymis-
orchitis, though for both the absolute risk was below 1%. Abdominal pain, previously reported in 
secondary care, was also associated but with a very low PPV of 0.1%.(11) Its significance as an 
indicator of testicular cancer rises above the NICE threshold when accompanied by testicular pain, 
lump or swelling. 
A raised LDH was not seen in controls, so we cannot estimate PPVs for it; however only 27 of the 71 
cases in which the LDH was measured had a raised value (<2% of all cases). We cannot know if the 
LDH was taken because testicular cancer was suspected or whether it was simply part of a battery of 
LFT tests. It is clear that a normal LDH does not rule out testicular cancer. The small number of 
positives do not at this stage support it being used as a diagnostic tool. 
 
 
Implications for practice 
Testicular lump and testicular swelling were each strongly associated with cancer in the under 50s 
age group, with PPVs of 2.5% and 2.3%, values just below the 3% threshold for urgent referral. The 
NICE guidance recommended urgent referral, using wording reflecting the lack of evidence at the 
time. Our results show that this recommendation was probably reasonable, especially as the 
guidance explicitly asked clinicians to use their judgement in deciding upon the merits of referral.  
Contrary to traditional teaching, painful testicular enlargement remains a strong predictor of cancer. 
In the over 50s age group, testicular enlargement collectively still produces a PPV of over 3% 
(testicular lump, 0.6%, testicular swelling, 0.4% and scrotal swelling, 2.1%). However, pain appeared 
to reduce the risk from enlargement in contrast to younger men. This may represent an increased 
frequency of infection. 
Recorded hydrocele, epididymis/orchitis or testicular pain (especially when these lead to a second 
consultation) are important features of testicular cancer in primary care. It is plausible either a 
hydrocele or infection could arise as a complication of testicular cancer; even so the fact that these 
presumptive or possibly erroneous diagnoses have an association with cancer makes them 
candidates for investigation. NICE guidance suggested ultrasound should be considered for 
‘unexplained or persistent’ testicular symptoms: this study suggests that recurrent testicular pain, 
unresolving epididymis-orchitis, or hydrocele should come within this recommendation.   
Other isolated features, in the upper row of Figure 2 are very low risk, and probably do not warrant 
initial investigation or referral, though good clinical practice would suggest some agreed form of 
review netting could be offered. However, non-testicular features such as abdominal pain, groin pain 
and raised inflammatory markers all warrant referral when combined with testicular pain. 
 
Conclusion 
These results largely support the UK recommendations for investigation of possible testicular cancer, 
though they provide additional information as to which symptoms or symptom combinations 
warrant ultrasound.  They also identify possible sources of delay in cancer diagnosis, such as 
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